Effect of incadronate on corticosteroid-induced osteopenia in rats.
The effect of incadronate, a third-generation bisphosphonate, was evaluated in rats with corticosteroid-induced osteopenia. Male Wistar rats were treated with methylprednisolone acetate (1 mg/kg, s.c.) once daily, 3 days a week for 12 weeks. Other groups received simultaneous treatment with methylprednisolone acetate and incadronate (0.03, 0.3 or 3 mg/kg, p.o.); incadronate was given once daily, 6 days a week for 12 weeks. Bone mineral densities (BMDs) of the second lumbar (L2) vertebra as well as the ultimate compressive strength of the fifth lumbar (L5) vertebra decreased. Incadronate dose-dependently inhibited the loss of L2 BMDs and the decrease in strength of the L5 vertebrae. These results suggest that incadronate may be effective in treating osteopenia accompanying corticosteroid therapy.
Takahashi
Koichiro
K
Inflammation Research, Pharmacology Research Laboratories, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Tsukuba City, Japan. takahasi@yamanouchi.co.jp
Fukushima
Shinji
S
Nozaki
Kazutoshi
K
Kokubo
Satoshi
S
Teramura
Kyoko
K
Miyata
Keiji
K
D000284:Administration, Oral; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D001851:Bone Diseases, Metabolic / Q000139:chemically induced* / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D019245:Compressive Strength / Q000187:drug effects; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D008159:Lumbar Vertebrae / Q000503:physiopathology; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D000077555:Methylprednisolone Acetate; D051381:Rats; D017207:Rats, Sprague-Dawley
D004164:Diphosphonates; C071542:cimadronate; D000077555:Methylprednisolone Acetate; D008775:Methylprednisolone